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X-linked Emery-Dreifuss muscular dystrophy is
caused by loss of function of emerin, an integral pro-
tein of the inner nuclear membrane. Yet emerin null
mice are essentially normal, suggesting the existence
of a critical compensating factor. We show that the
lamina-associated polypeptide1 (LAP1) interacts
with emerin. Conditional deletion of LAP1 from stri-
atedmuscle causesmuscular dystrophy; this pathol-
ogy is worsened in the absence of emerin. LAP1
levels are significantly higher in mouse than human
skeletal muscle, and reducing LAP1 by approxi-
mately half inmicealso inducesmuscle abnormalities
in emerin null mice. Conditional deletion of LAP1 from
hepatocytes yields mice that exhibit normal liver
function and are indistinguishable from littermate
controls. These results establish that LAP1 interacts
physically and functionally with emerin and plays an
essential and selective role in skeletalmusclemainte-
nance. They also highlight howdissectingdifferences
between mouse and human phenotypes can provide
fundamental insights into disease mechanisms.
INTRODUCTION
Mutations in genes encoding nuclear envelope proteins cause
tissue-specific diseases called ‘‘laminopathies’’ or ‘‘nuclear
envelopathies’’ (Dauer and Worman, 2009). For example, domi-
nant or recessively inherited mutations in LMNA encoding the
A-type nuclear lamins cause Emery-Dreifuss muscular dystro-
phy (EDMD) and phenotypically related myopathies (Bonne
et al., 1999; Fatkin et al., 1999; Muchir et al., 2000; Brodsky
et al., 2000; Di Barletta et al., 2000). EDMD is also inherited as
an X-linked disorder caused by mutations in the gene EMD en-
coding emerin (Bione et al., 1994), an integral protein of the inner
nuclear membrane (INM) that interacts with A-type lamins (Man-
ilal et al., 1996; Nagano et al., 1996; Fairley et al., 1999; SullivanDevelopmenet al., 1999; Clements et al., 2000). Different mutations in LMNA
cause diseases primarily affecting other tissue types, such as fat
or peripheral nerve (Dauer and Worman, 2009).
To better understand how alterations in nuclear envelope pro-
teins cause disease, we initiated ‘‘interactome’’ screens with
integral proteins of the INM. We began with lamina-associated
polypeptide 1 (LAP1), a type II integral protein of the INM (Senior
and Gerace, 1988), because of its interactions with proteins
linked to tissue-selective disease. The luminal domain of LAP1
binds to torsinA, the defective protein in the CNS specific dis-
ease DYT1 dystonia (Goodchild and Dauer, 2005), and its nucle-
oplasmic domain binds to lamin A (Foisner and Gerace, 1993;
Maison et al., 1997; Senior and Gerace, 1988).
We find that LAP1 interacts with emerin, the X-linked EDMD
protein and show that conditional deletion of LAP1 from mouse
muscle causes muscular dystrophy leading to early lethality. In
contrast, conditional deletion of LAP1 from the liver has little or
no effect at the organismal or cellular level. Although emerin
null mice do not develop myopathy, emerin deficiency signifi-
cantly worsens the muscular dystrophy and shortens the life-
span of mice lacking LAP1 in skeletal muscle, thus establishing
a vertebrate model system in which the effects of emerin disrup-
tion on muscle pathology can be studied. The level of LAP1 in
skeletal muscle of mice is approximately double that of humans
and reducing it by 50% causes a mild myopathy in emerin null
mice. These data demonstrate an essential and selective role for
LAP1 in striated muscle and suggest strongly that the difference
in the level of skeletal LAP1 is a key factor underlying the con-
sequences of emerin loss of function in humans and mice. This
relationship between LAP1 and emerin is reminiscent of that
between dystrophin and utrophin, which contributes to the
distinct consequences of dystrophin deletion in human and
mouse (Deconinck et al., 1997; Grady et al., 1997).RESULTS
Emerin Interacts with LAP1
We conducted an unbiased ‘‘interactome’’ screen to identify
LAP1-binding proteins. HEK293 cells were stably transfected
with a construct that expressed V5 epitope-tagged LAP1.tal Cell 26, 591–603, September 30, 2013 ª2013 Elsevier Inc. 591
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Figure 1. LAP1 and Emerin Coimmunoprecipitate from Cell Extracts
(A) Endogenous emerin was coimmunoprecipitated with overexpressed V5-tagged LAP1 in HEK293 cells. Protein extracts from uninduced ( DOX) or induced
(+ DOX) cells were collected and immunoprecipitated (IP) with anti-V5 antibodies. Protein inputs (1% of total lysate) and precipitated products were separated by
SDS-PAGE, transferred to nitrocellulose, and probed with antibodies against V5, emerin, Man1, LAP2b, and lamin A, the migrations of which are indicated.
Migrations of molecular mass standards in KDa are indicated at the left of the blots.
(B) Protein extracts fromHEK293 cells were incubated with anti-emerin (4G5), isotypematched anti-immunoglobulin G (IgG), and agarose beadswith no antibody
for coimmunoprecipitation. LAP1 coimmunoprecipitated with emerin but LAP2b did not as indicated in the immunoblot. The double band of emerin may be due to
differential phosphorylation. Bands corresponding to IgG heavy and light chains are indicated andmigrations ofmolecularmass standards in KDa are indicated at
the left of the blots.
(C) In vitro pull-down assay showed that LAP1 binds to the nucleoplasmic domain of emerin. Immunoblot shows the input and GST-LAP1 and V5-tagged LAP1
purified fromHEK293 cells fused to agarose beads pulled down purifiedMBP-emerin fusion protein but not purifiedMBP. Analysis of bacterially expressedMBP-
emerin showed intact protein (*) and smaller fragments (bracket). Migrations of molecular mass standards in KDa are indicated at the left of the blots.
(D) Schematic diagram of full-length human LAP1 (LAP1-FL), the nucleoplasmic domain plus transmembrane segment (LAP1-Nuc) and luminal domain plus
transmembrane segment (LAP1-Lum) expressed in HEK293 cells for the coimmunoprecipitation experiments shown in (E). Red indicated V5 epitope and blue the
transmembrane segment; amino acid residues 1, 330, 360, and 584 are indicated. The blue mesh indicates the relative position of the nuclear lamins and green
rectangles the inner (INM) and outer (ONM) nuclear membranes (not to scale).
(E) Full-length LAP1 and the nucleoplasmic domain plus transmembrane segment bind emerin but the luminal domain plus the transmembrane segment does not.
HEK293 cells were transfected with vector only or plasmids expressing V5 tagged fusions of LAP1 as indicated. Protein extracts were collected and immu-
noprecipitated (IP) with anti-V5 antibodies. Protein inputs (1% of total lysate) and precipitated products were separated by SDS-PAGE, transferred to nitro-
cellulose and probed with antibodies against V5 or emerin as indicated. Migrations of molecular mass standards in KDa are indicated at the left of the blots.
See also Table S1.
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LAP1, Emerin, and Striated Muscle MaintenanceImmunoprecipitates of protein extracts from induced cells ob-
tained using anti-V5 antibodies were analyzed by mass spec-
troscopy. This analysis identified emerin with the highest score
among candidates (Table S1 available online).
We performed several experiments to confirm that emerin is a
bona fide LAP1-interacting protein. We first repeated coimmu-
noprecipitations in stably transfected HEK293 cells with the
inducible construct encoding V5 epitope-tagged LAP1. Endoge-
nous emerin was coprecipitated by anti-V5 antibodies from
protein extracts of induced cells but not from uninduced cells
(Figure 1A). Neither MAN1 nor LAP2b that share the LEM domain592 Developmental Cell 26, 591–603, September 30, 2013 ª2013 Elswith emerin were coprecipitated. A small quantity of lamin A,
which binds LAP1 and emerin, was identified in immunoprecip-
itates (Figure 1A). To examine the emerin-LAP1 interaction at
endogenous protein levels, we performed coimmunoprecipita-
tion in untransfected HEK293 cells with anti-emerin antibodies.
In these experiments, endogenous LAP1 was coimmunoprecipi-
tated but LAP2b was not (Figure 1B). We further expressed the
nucleoplasmic domain of emerin devoid of its transmembrane
segment as a maltose-binding protein (MBP) fusion in bacteria,
purified it, and incubated it with a glutathione-S-transferase
(GST) or a V5 fusion of full-length LAP1 purified from transfectedevier Inc.
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Figure 2. FRET Analysis of LAP1 and Emerin
Association in Cells
(A) Representative images of a cell expressing
RFP-emerin (Acceptor) and GFP-LAP1 (Donor).
Images were taken before (upper) and after (lower)
photobleach of RFP-emerin in the boxed region of
interest (ROI). In the two right images (LAP1 and
LAP1 Zoomed), intensities of GFP-LAP1 signals
weremapped as colors in a rainbowspectrum from
low and high fluorescence intensity as indicated;
red signals demonstrate increased GFP-LAP1
fluorescence and show increased fluorescent
intensity after a photobleaching. Scale bar: 5 mm.
(B) Calculated FRET energy transfers between the
protein pairs indicated. Values are means ± SEMs;
n = 15, ***p < 0.0001.
(C) Acceptor (RFP) fluorescence intensities prior to
photobleaching (x axis) plotted against energy
transfers (y axis) for the protein pairs indicated.
Linear regression analysis of the plotted data sets
of the indicated protein pairs showed no correla-
tion between fluorescence intensities and FRET
percentage energy transfers, confirming that the
binding of protein pairs was specific.
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LAP1, Emerin, and Striated Muscle MaintenanceHEK293 cells on GST or V5 agarose (Figure 1C). The MBP-
emerin fusion protein, but not MBP alone, bound to the LAP1
fusions attached to the GST or V5 agarose (Figure 1C). This sug-
gested that LAP1 interacts with emerin specifically through its
nucleoplasmic domain. We tested this prediction by performing
domain-mapping experiments with emerin and LAP1 or LAP1
fragments expressed in HEK293 cells. We transfected HEK293
cells with cDNAs encoding V5-tagged full-length LAP1, LAP1
nucleoplasmic plus transmembrane domain (first 360 amino
acids) or LAP1 transmembrane plus luminal domain (amino acids
330–584; Figure 1D). Immunoprecipitation with anti-V5 anti-
bodies showed that endogenous emerin coimmunoprecipitated
with full-length or nucleoplasmic plus transmembrane domain
constructs but not with the transmembrane plus luminal domain
construct (Figure 1E). Hence, emerin and LAP1 interact through
their nucleoplasmic domains.
We next used fluorescence resonance energy transfer (FRET)
acceptor photobleaching to examine the LAP1-emerin interac-
tion in cells. With this method, increases in donor fluorescence
after acceptor photobleaching measures efficiency of energy
transfer (representing physical proximity) between two proteins.
As a positive control, we used the GFP-lamin A/RFP-emerin pair.
For negative controls, we used either GFP-LAP1/RFP or GFP/
RFP-emerin pairs. Energy transfer efficiency between GFP-
LAP1 and RFP-emerin was significantly greater than both nega-
tive control pairs, confirming that emerin and LAP1 interact in
cells (Figures 2A and 2B). Energy transfer was independent of
the intensity of acceptor fluorescence (Figure 2C), indicatingDevelopmental Cell 26, 591–603, Sethe FRET was not a random distribution
effect but occurred as a result of specific
binding between donor and acceptor
molecules (Periasamy et al., 2008).
To obtain further evidence that LAP1
interacts with emerin, we examined the
effects of depletion of these proteins oneach other’s subcellular localization. In LAP1 null fibroblasts,
emerin mislocalized to distinct foci along the nuclear envelope
in approximately 30% of cells examined (Figure 3A). A-type lam-
ins colocalized with emerin in these abnormal foci, yet all other
nuclear envelope proteins examined exhibited a normal distribu-
tion pattern, including lamin B1, LBR (an integral INM protein),
and Nup98 (a nuclear pore complex protein; Figure 3B). LAP1
null cells exhibited normal morphology of ER and Golgi (data
not shown) and normal amounts of emerin, lamin A, lamin C,
and lamin B1 compared to wild-type cells (Figure 3C). We also
found that in emerin null fibroblasts LAP1 expression was mildly
reduced but its localization in the nuclear envelope was unal-
tered (Figures S1A and S1B). These data further support a phys-
ical interaction between emerin and LAP1 and indicate that LAP1
is required for normal localization of a subpopulation of emerin/
A-type lamin complexes.
We next testedwhether depleting emerin or LAP1 changed the
behavior of the other in cells. Emerin diffuses within the nuclear
envelope membranes (O¨stlund et al., 1999), so we tested if its
diffusional mobility was altered in the absence of LAP1 using
fluorescence recovery after photobleaching (FRAP). GFP-emerin
recovered more quickly in fibroblasts lacking LAP1, although the
initial mobility rates as measured by half-times were not signifi-
cantly different between cell types (Figure 3D). Similar to the
limited effects on localization observed in emerin null cells,
LAP1 mobility was unchanged in the absence of emerin (data
not shown). These findings show that LAP1 contributes to the
immobilization of emerin in the INM, but other proteins such asptember 30, 2013 ª2013 Elsevier Inc. 593
Figure 3. Mislocalization of Emerin and Lamin A in LAP1 Null Fibroblasts
(A) Confocal immunofluorescence micrographs showing emerin localization in fibroblasts from wild-type (WT) and LAP1 null mice. Cells were labeled with
antibodies against emerin (green) and LAP1 (red) with colocalization showing as yellow (overlay); in overlays counterstaining of nuclei with DAPI (blue) is also
shown. Scale bar, 10 mm.
(B) Confocal immunofluorescence micrographs showing the localization of emerin and other indicated proteins in LAP1 null fibroblasts. Cells were labeled with
antibodies against emerin (green) and the other indicated protein (red) with colocalization showing as yellow (overlay). Scale bar, 10 mm.
(C) Proteins in extracts from fibroblasts of three different LAP1 null and control mice were collected and subjected to immunoblot analysis using antibodies
against LAP1, emerin, lamin A/C, lamin B1 and GADPH. Migrations of molecular mass standards in KDa are indicated at the left of the blots.
(D) FRAP analysis of GFP-emerin in transfected wild-type and LAP1 null mouse fibroblasts. Curve shows normalized fluorescence versus time after photo-
bleaching an area of the nuclear envelope. Data at each measured time point are means ± SD (n = 20 for control cells; n = 22 for LAP1 null cells).
See also Figure S1.
Developmental Cell
LAP1, Emerin, and Striated Muscle MaintenanceA-type lamins likely play a more significant role (Sullivan et al.,
1999; O¨stlund et al., 1999, 2006).
Conditional Deletion of LAP1 from Muscle Causes
Muscular Dystrophy
Loss of emerin causes EDMD in humans (Astejada et al., 2007;
Bione et al., 1994;Manilal et al., 1996; Nagano et al., 1996). How-
ever, emerin null mice have a normal lifespan and do not develop
overt muscle pathology (Melcon et al., 2006; Ozawa et al., 2006).
To begin to explore the mechanism for this striking species dif-
ference, we examined the relative levels of LAP1 and emerin in
human and mouse skeletal muscle. Western blot analysis of
emerin using antibodies recognizing both the mouse and human594 Developmental Cell 26, 591–603, September 30, 2013 ª2013 Elsproteins revealed that mouse skeletal muscle has diminished
expression compared to human (Figures 4A and 4B). Similar
results were obtained using anti-emerin antibodies obtained
from three different sources provided in the Supplemental
Experimental Procedures (data not shown). Conversely, LAP1
expression was significantly higher in mouse than human stri-
ated muscle (Figures 4A and 4B). These differences in the rela-
tive levels of LAP1 and emerin suggested that mouse skeletal
muscle may be less dependent upon emerin function and poten-
tially protected by high levels of LAP1. To test for such a
functional effect of LAP1 that might parallel its interaction with
emerin, we explored the effects of LAP1 depletion in vivo in
mouse striated muscle. Because germline deletion causesevier Inc.
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Figure 4. Striated Muscle-Selective Deletion of LAP1 in Mice Produces Shortened Lifespan with Progressive Muscle and Body Mass Loss
(A) Immunoblots of protein extracts of lateral quadriceps muscle from normal adult humans and 6-week-old wild-type C57/B6 mice. Blots were probed with
antibodies against emerin, LAP1 and GAPDH. Each lane is a sample from a different subject.
(B) Quantification of emerin and LAP1 expression normalized to GAPDH in protein extracts of mouse (n = 6) and human (n = 4) muscle samples. Values are
means ± SEM; ***p < 0.0001, **p < 0.005.
(C) Photos of a littermate control (Tor1aip1f/f) and an M-CKO (Mck-Cre+/;Tor1aip1f/f) mouse at 12 weeks of age.
(D) Body mass of male M-CKO and control (Tor1aip1f/f) mice versus age. Values are means ± SEM; *p < 0.05, **p < 0.005, ***p < 0.0005.
(E) Kaplan-Meier survival curves for male Tor1aip1f/f control and male M-CKO mice.
(F)Photosofskinnedhindlimbs froma littermatecontrol (Tor1aip1f/f) andanM-CKOmouseat16weeksofageshowingdecreasedmusclemass in theM-CKOmouse.
(G) Muscle mass to tibia length ratio of quadriceps (Q), gastrocnemius medialis (Gs-m), tibialis anterior (Ti), and soleus (Sol) muscles of Tor1aip1f/f control (n = 5)
and M-CKO (n = 7) mice at 16 weeks of age. Values are means ± SEM; ***p < 0.0005.
(H) Serum creatine phosphokinase (CPK) activities in Tor1aip1f/f control (n = 11) andM-CKO (n = 8) mice at 8–9 weeks of age. The upper limit cut-off of the assay is
1,200 U/l. Values for each individual control (circles) and M-CKO (triangles) mouse are given and the horizontal bars are the mean values; *p < 0.05.
(I) Grip strength (kg force per kg) in Tor1aip1f/f control (n = 8) and M-CKO (n = 6) mice at 8–9 and 11–12 weeks of age. Values are means ± SEM; **p < 0.005,
***p < 0.0005.
See also Figure S2.
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LAP1, Emerin, and Striated Muscle Maintenanceperinatal lethality (Kim et al., 2010), we floxed Tor1aip1 encoding
LAP1 (Figure S2A) to conditionally delete LAP1 from striated
muscle, usingMck-Cre transgenic mice that express Cre recom-
binase selectively in striated muscle. The Mck promoter is ex-
pressed at approximately E17 in differentiating striated muscle
of mouse embryos (Bru¨ning et al., 1998; Beedle et al., 2012).
Mck-Cre+/;Tor1aip1f/f mice (‘‘M-CKO’’ for muscle-selective
conditional knockout) exhibited efficient and specific recombi-
nation at the Tor1aip1 locus in striated muscle but not in liver
or lung (Figure S2B). LAP1 was depleted selectively in protein
lysates from muscle (Figures S2C and S2D) and undetectable
in myofibers (Figure S2E).
M-CKOmice were born at the expected Mendelian frequency
and initially indistinguishable from Tor1aip1f/f littermate controls.DevelopmenHowever, at approximately 8 weeks of age, they stopped gaining
weight, and over the next 4–6 weeks became noticeably smaller
than littermate controls and developed an abnormal hunched
posture (Figure 4C). M-CKO mice became significantly lighter
than littermate controls by 12 weeks of age and continued to
lose weight until dying prematurely (Figure 4D). This was the
same for both sexes (data not shown). Body mass versus age
of Tor1aip1f/f control littermates was indistinguishable from
both wild-type and Mck-Cre mice (data not shown). Male
M-CKO mice had a median survival of approximately 150 days
with 100%mortality by 211 days whereas 100% of controls sur-
vived until they were sacrificed at 275 days (Figure 4E). Similar
results were obtained for female mice (data not shown). By
16 weeks of age, M-CKO mice had gross atrophy of multipletal Cell 26, 591–603, September 30, 2013 ª2013 Elsevier Inc. 595
Developmental Cell
LAP1, Emerin, and Striated Muscle Maintenancemuscle groups compared to littermate controls (Figures 4F and
4G). Serum creatine phosphokinase activity was significantly
elevated in M-CKO mice compared to age-matched controls
with half having a value of 1,200 U, the assay cutoff (Figure 4H).
M-CKO mice also had decreased grip strength compared to
controls (Figure 4I). These results demonstrate that loss of
LAP1 function from striated muscle causes a profound myop-
athy resulting in early death.
Histopathological analysis of skeletal muscle from M-CKO
mice showed classical features ofmuscular dystrophy that wors-
ened with age. Hematoxylin and eosin-stained sections of
gastrocnemius muscle showed that M-CKO muscle appeared
normal at 6 weeks but showed degenerative/regenerative fibers
by 9weeks anddegenerative/regenerative fibers, centralmyonu-
clei and myonuclei arrays by 12 weeks (Figure 5A). Similar path-
ological features were found in the tibialis anterior, soleus, and
diaphragm at 12 weeks of age (Figure S3A). Muscle fibers from
Mck-Cremice did not show these changes and therewere no dif-
ferences between male and female M-CKO mice (data not
shown). By 9 weeks, there was a significant decrease in quadri-
ceps muscle fiber area in M-CKO mice compared to controls
(Figure 5B) and by 12weeks approximately 40%of themyofibers
had central nuclei (Figure 5C). At 16 weeks of age, quadriceps
muscle from M-CKO mice had significantly increased fibrosis,
which was virtually absent in controls (Figures 5D–5F). Electron
micrographs of quadriceps muscle showed changes consistent
with a profound myopathy, including disorganized myofibrils,
increased sarcomere length, dispersed glycogen particles, and
enlarged mitochondria and nuclei (Figure 5G).
Immunofluorescencemicroscopic analysis of isolatedmyofib-
ers from skeletal muscle of M-CKO revealed frequent enlarged
nuclei with ruffled borders when labeled with anti-lamin A anti-
bodies and approximately 10% exhibited punctate nuclear
foci recognized by anti-emerin antibodies (Figure S3B). The
abnormal localization of emerin was similar to that observed in
embryonic fibroblasts of LAP1 null mice. Analysis of myofiber
types showed an increase in type IIa fibers and a decrease in
type IIb fibers in gastrocnemius but not soleus muscle from
M-CKO mice compared to wild-type mice at 16 weeks of age
(Figures S3C and S3D). In Duchenne muscular dystrophy, type
IIb fibers are the first to degenerate and a transformation into
type IIa fibers has been postulated to occur (Webster et al.,
1988; Pedemonte et al., 1999).
Conditional Deletion of LAP1 from Liver Causes No
Overt Phenotype
Tissues of endodermal origin are not typically affected in human
nuclear envelope-related diseases. Specifically, liver disease
does not develop in patients with EDMD caused by mutations
in EMD. To determine whether our findings in M-CKO mice
represent a unique requirement of muscle tissue for LAP1, or
reflect a nonspecific role, we conditionally deleted LAP1 from
hepatocytes using Alb-Cre transgenic mice that expressCre un-
der control of an albumin promoter. Alb-Cre+/;Tor1aip1f/f mice
(‘‘L-CKO’’ for liver-selective conditional knockout) mice ex-
hibited efficient and specific recombination at the Tor1aip1 locus
in liver but not in lung or striated muscle (Figure S4A). LAP1 was
depleted selectively in protein lysates from liver (Figures S4B and
S4C) and undetectable in hepatocytes (Figure S4D).596 Developmental Cell 26, 591–603, September 30, 2013 ª2013 ElsIn marked contrast to the profound phenotype of M-CKO
mice, L-CKO mice (Figure 6A) were indistinguishable from their
littermate controls at all ages examined, up to 23 months.
Weight gain (Figure 6B), liver size (Figure 6C) and liver to
body mass ratio (Figure 6D) were normal. Moreover, hepato-
cyte integrity and liver function appeared unaffected, as evi-
denced by normal mean serum activities of aspartate and
alanine aminotransferases and serum concentrations of bili-
rubin and albumin (Figure 6E). Histopathological examination
of livers from 16 week-old L-CKO showed essentially normal
overall tissue organization except for some slight narrowing of
the sinusoidal spaces and there was no evidence of hepatitis
or cirrhosis (Figure 6F). Hepatocyte nuclei did show an increase
in size (Figure 6G). Lifespan of L-CKO mice followed for up to
690 days did not differ from controls (Figure 6H). Both male
and female L-CKO mice were fertile up to 1 year of age. These
data demonstrate that LAP1 is not essential in all tissues, high-
lighting the specificity and importance of LAP1 function in
muscle.
Our data demonstrating a physical interaction between LAP1
and emerin suggest that these proteins may be functionally
related and could potentially compensate for each other’s
absence. We therefore examined the relative levels of emerin
in mouse muscle and liver and found that both tissues express
similar levels (Figure 6I), eliminating the possibility that emerin
‘‘masks’’ an essential role for LAP1 in M-CKO mouse muscle.
The lack of phenotype in L-CKO mice is even more striking
considering that there is significantly more LAP1 in liver than in
muscle (Figure 6I). The relevance of the mouse model to human
liver is supported by the finding of similar relative amounts of
LAP1 and emerin in human liver (Figure 6J). Considered
together, these data demonstrate that LAP1 is not essential in
all tissues, highlighting the specificity and importance of LAP1
function in muscle.
Functional Interaction of LAP1 and Emerin Deletion
in Mouse Striated Muscle
Having established that LAP1 binds to emerin and plays a spe-
cific and essential role in muscle maintenance, we next tested
whether these proteins functionally interact in vivo in skeletal
muscle, the main tissue disrupted in EDMD. We explored this
question by generating mice that lacked LAP1 in striated muscle
on an emerin null background (M-CKO;Emd/y mice). The fact
that emerin null mice do not develop myopathy (or any other
overt phenotype) and exhibit a normal lifespan (Melcon et al.,
2006; Ozawa et al., 2006) eliminated the confounding situation
inherent in testing for a functional interaction between two genes
when each has an independent loss-of-function phenotype.
Consistent with previous reports (Melcon et al., 2006; Ozawa
et al., 2006), loss of emerin alone (Emd/y mice) did not affect
lifespan (Figure 7A) or cause myopathy (data not shown). In
contrast, loss of emerin function significantly decreased the
lifespan and exacerbated the myopathy ofM-CKOmice (Figures
7A–7C), reducing median survival by more than half (median
survival: M-CKO;Emd+/y = 150 d; M-CKO;Emd/y = 69 days;
Figure 7A). Similarly, loss of emerin function enhanced the
severity of skeletal muscle myopathic change seen in M-CKO
mice (Figure 7B). To quantify this effect, we had the tissue
independently examined by two neuromuscular pathologistsevier Inc.
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Figure 5. Histopathological Analysis of Skeletal Muscle from M-CKO Mice
(A) Representative hematoxylin and eosin-stained cross and longitudinal sections of quadriceps muscle from Tor1aip1f/f control andM-CKOmice at 9 (9W) and
12 (12W) weeks of age (three mice were analyzed per each group). Black arrows indicate degenerative/necrotic fibers, black arrowheads indicate central nuclei
and white arrowheads indicate myonuclei arrays. Bars: 50 mm.
(B)Mean ± SEMof cross-sectional fiber areas in quadriceps from Tor1aip1f/f control andM-CKOmice at 6 (6W), 9 (9W), and 12 (12W) weeks of age. Three different
regions of each section from three different animals per group (n = 9) were analyzed. Values are means ± SEM; *p < 0.01; **p < 0.001.
(C) Quantification of central nuclei in sections of quadriceps from Tor1aip1f/f control andM-CKOmice at 9 (9W) and 12 (12W)weeks of age. Three different regions
from each section were counted (three sections per animal; three animals per each age group). Note that about 40% of myofibers have central nuclei in
quadriceps of 12-week-old M-CKO mice. Values are means ± SEM; ***p < 0.0001.
(D) Representative micrographs of sections of quadriceps muscle stained with Masson’s trichrome from Tor1aip1f/f control mice (Control-16W) andM-CKOmice
(M-CKO-16W) at 16 weeks of age. Areas of fibrosis stain blue. Scale bar, 50 mm.
(E) Hue histograms of micrographs in (D) in which colors are represented from 0 to 255 units (blue 140–200 units) versus area of tissue section. The y axis gives
area (pixels) and the x axis the color spectrum with red for muscle tissue and blue (140–200 units) for connective tissue.
(F) Percentage of fibrosis per surface area of muscle. Sections of quadriceps from 16-week-old Tor1aip1f/f mice (Control-16W) and M-CKO mice were stained
with Masson’s trichrome measured as described in (D). Three different regions from each section from three different animals per group (n = 9) were analyzed.
Values are means ± SEM; **p < 0.005.
(G) Representative electron micrographs of sections of quadriceps muscle from Tor1aip1f/f control mice (Control-12W) and M-CKO mice (M-CKO-12W) at
12 weeks of age. Bars: 2 mm. White arrowhead indicates an enlarged nucleus, black bracket indicates dispersed glycogen particles, and black arrows indicate
enlarged mitochondria in muscle sections from an M-CKO mouse.
See also Figure S3.
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LAP1, Emerin, and Striated Muscle Maintenanceunaware of the genotype (or each other’s assessment). The
severity scoresweremostly concordant between the two pathol-
ogists: the myopathy was more severe in M-CKO;Emd/y mice
compared to maleM-CKOmice (difference in severity score be-
tween genotypes was significant at p = 0.0369 for Pathologist 1
and p = 0.0516 for Pathologist 2). We next examined M-CKO
heterozygous;Emd/y mice to test if reduction of LAP1 byDevelopmenapproximately half—to roughly the levels present in human
muscle—would cause myopathic features on an emerin null
background. M-CKO heterozygous;Emd/y mice showed mild
myopathic changes including the presence of occasional
degenerative myofibers (Figure 7D). Consistent with this
histopathological evidence of myopathy, M-CKO hetero-
zygous;Emd/y mice exhibit significantly elevated serum levelstal Cell 26, 591–603, September 30, 2013 ª2013 Elsevier Inc. 597
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Figure 6. Analysis of Mice with Liver-Selective Deletion of LAP1
(A) Photos of a littermate control (Tor1aip1f/f) and L-CKO (Alb-Cre+/;Tor1aip1f/f) mouse at 16 weeks of age.
(B) Body mass of male L-CKO and control (Tor1aip1f/f) mice versus age. Values are means ± SEM; differences between genotypes were not significant.
(C) Photos of livers from a littermate control (Tor1aip1f/f) and an L-CKO mouse at 16 weeks of age.
(D) Liver to body mass ratio of Tor1aip1f/f control (n = 6) and L-CKO (n = 10) mice at 16 weeks of age. Values are means ± SEM; NS, not statistically significant.
(E) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities and albumin and bilirubin concentrations in Tor1aip1f/f control litter-
mates (n = 9) and L-CKO (n = 9) mice at 16 weeks of age and normal reference ranges for these parameters in the Comparative Pathology Laboratory at Columbia
University Medical Center. Values are means ± SEM.
(F) Representative hematoxylin and eosin-stained sections of liver from Tor1aip1f/f control mice and L-CKO mice at 16 weeks of age. Scale bar, 50 mm.
(G) Bar graph shows mean ± SEM of nuclear area per hepatocyte for Tor1aip1f/f control mice and L-CKO mice at 16 weeks of age; n = 100, **p < 0.005.
(H) Kaplan-Meier survival curves formale Tor1aip1f/f control andmale L-CKOmice.Miceweremonitored up to 690 days of age; onemouse per each group died at
ages greater than 400 days.
(I) Immunoblots of protein extracts of skeletal muscle (Sk. Muscle) and liver from 6-week-old wild-type C57/B6 mice. Blots were probed with antibodies against
emerin and LAP1. Ponceau S-stained nitrocellulose sheet shows similar amounts of protein loading (20 mg of protein/lane) for each sample. Migrations of
molecular mass standards in KDa are indicated at the left. Signal intensity was measured and averaged for emerin and LAP1 bands (bottom panel). Values are
means ± SEM. **p < 0.005.
(J) Immunoblots of protein extracts of human skeletal muscle (Sk. Muscle) and liver. Blots were probed with antibodies against emerin and LAP1. Ponceau
S-stained nitrocellulose sheet shows similar amounts of protein loading (20 mg of protein/ lane) for each sample. Migrations of molecular mass standards in KDa
are indicated at the left. Signal intensity was measured and averaged for emerin and LAP1 bands (bottom panel). Values are means ± SEM. ***p < 0.0001.
See also Figure S4.
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LAP1, Emerin, and Striated Muscle Maintenanceof creatine phosphokinase activity (Figure 7E). These mice did
not exhibit overt behavioral abnormalities or reduced lifespan
(data not shown). Considered together, these results suggest
that emerin and LAP1 function together in skeletal muscle func-
tion and maintenance.598 Developmental Cell 26, 591–603, September 30, 2013 ª2013 ElsDISCUSSION
Emerin loss of function causes EDMD in humans, but progress
in understanding the pathogenesis of this muscular dystrophy
has been hampered by the lack of any model in which emerinevier Inc.
Figure 7. Shortened Lifespan and More Severe Myopathy in Mice with Combined Striated Muscle-Selective LAP1 and Emerin Depletion
(A) Kaplan-Meier survival curves for male M-CKO, M-CKO;Emd/y and Tor1aip1f/f;Emd/y (Control;Emd/y) mice. Log-rank test was used to compare survival
curves. The difference between M-CKO and M-CKO;Emd/y mice was statistically significant (p < 0.0001).
(B) Representative hematoxylin and eosin-stained transverse and longitudinal sections of quadriceps from male M-CKO and M-CKO;Emd/y mice. Scale
bar, 50 mm.
(C) Myopathy severity scores of histopathological examinations for skeletal muscle from male M-CKO and M-CKO;Emd/y mice. Individual scores for samples
from seven male M-CKO and 7 M-CKO;Emd/y mice and mean ± SEM score given by two independent, blinded neuromuscular pathologists are shown. The
p values for severity score differences between M-CKO and M-CKO;Emd/y mice of each pathologist are shown.
(D) Hematoxylin and eosin-stained cross- and longitudinal sections of quadriceps muscle from Control;Emd null (Tor1aip1f/f;Emd null) andM-CKO het;Emd null
(Mck-Cre+/;Tor1aip1f/+;Emd null) mice at 10weeks of age. Muscle sections from eightmice per each group were blindly examined by a pathologist. The sections
from the Control;Emd null group showed no pathology, while the sections from two of eight M-CKO het;Emd null mice displayed occasional degenerative/
necrotic fibers as indicated by arrowheads.
(E) Serum creatine phosphokinase (CPK) activities in Control;Emd null (n = 12) andM-CKO het;Emd null mice (n = 15) at 8–11weeks of age. The upper limit cut-off
of the assay is 1,200 U/l. Values for each individual Control;Emd null (circles) andM-CKO het;Emd null (triangles) mouse are given and the horizontal bars are the
mean values; *p < 0.05.
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LAP1, Emerin, and Striated Muscle Maintenanceloss-of-function causes overt muscle pathology. We identify
LAP1 as an emerin-interacting protein and develop a model
in which emerin loss of function causes overt skeletal muscle
pathology with features of EDMD. The central myonuclei,
myofiber degeneration and regeneration, and elevated serum
creatine phosphokinase in the mice are typical of muscular
dystrophy. LAP1 thus represents an emerin-interacting pro-
tein to be functionally validated in the context of muscularDevelopmendystrophy and appears to have a selective function in striated
muscle. We also identify differences in the relative levels
of emerin and LAP1 in human and mouse skeletal muscle
that, based on additional in vivo findings, appear to account
for the lack of muscular dystrophy phenotypes in previous
emerin null mouse models. Considered together, our results
demonstrate a physical and functional relationship between
LAP1 and emerin in postnatal striated muscle maintenancetal Cell 26, 591–603, September 30, 2013 ª2013 Elsevier Inc. 599
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LAP1, Emerin, and Striated Muscle Maintenanceand establish a valuable model system to dissect the patho-
genesis of X-linked EDMD.
Emerin has been reported to bind to ten or more proteins
(Holaska and Wilson, 2007; Wilson and Foisner, 2010). A-type
lamins are the best-characterized emerin binding proteins (Fair-
ley et al., 1999; Sullivan et al., 1999; Clements et al., 2000).
Mutations in the gene encoding A-type lamins causemyopathies
including autosomal EDMD (Bonne et al., 1999; Fatkin et al.,
1999; Muchir et al., 2000; Brodsky et al., 2000; Di Barletta
et al., 2000). Deletion of A-type lamins and expression of variants
that cause EDMD lead to changes in emerin localization (Sullivan
et al., 1999; O¨stlund et al., 2006; Raharjo et al., 2001). However, it
remains unknown whether the muscle diseases caused by alter-
ations in A-type lamins involve emerin dysfunction because
epistatic studies between respective mouse mutants have not
been reported. Emerin interacts with the transcription factor
Lmo7 and inhibits its binding to promoters of MyoD and Pax3,
which are involved in myogenic differentiation (Dedeic et al.,
2011). Deletion of Lmo7 and a neighboring gene Uchl3 lead to
skeletal muscle degeneration and multiple other defects in
mice, but a potential role for emerin has not been elucidated
(Semenova et al., 2003). None of the other reported emerin-bind-
ing proteins has been related to muscle pathology.
We identify a physical relationship between emerin and LAP1
and, in contrast to previously identified emerin-interacting pro-
teins, present in vivo studies demonstrating clearly that loss
of LAP1 causes myopathy sufficiently severe to cause early
lethality. Furthermore, we demonstrate that LAP1 loss of func-
tion does not impair hepatocyte function, indicating a specific
role for LAP1 in striated muscle. The dramatic difference
between LAP1 loss-of-function in striated muscle and hepato-
cytes is consistent with several observations indicating a partic-
ular susceptibility of striated muscle to nuclear envelope
dysfunction (Roux and Burke, 2007; Dauer and Worman, 2009).
The vast majority of EDMD-causing EMD mutations abolish
emerin expression (Bione et al., 1994; Manilal et al., 1996;
Nagano et al., 1996; Yates and Wehnert, 1999). Subjects with
these mutations show no apparent abnormalities at birth. Joint
contractures typically occur in the first decade of life, progres-
sive muscle weakness and wasting in the second decade
and cardiomyopathy in the second decade or later (Emery
and Dreifuss, 1966). This classical clinical phenotype, as well
as variations that can occur with EMD mutations (Astejada
et al., 2007), indicates that emerin is dispensable for grossly
normal striated muscle development but essential for postnatal
muscle maintenance. This pattern of normal muscle develop-
ment and later degeneration is recapitulated in our models.
Moreover, in preliminary experiments, we find that M-CKO
mice lacking LAP1 and both LAP1 and emerin in striated muscle
have significantly decreased left ventricular fractional short-
ening compared to control mice at 9–11 weeks of age (data
not shown).
Unlike humans, emerin null mice do not develop overt signs of
myopathy postnatally (Melcon et al., 2006; Ozawa et al., 2006).
Following toxin-induced muscle damage, regenerating skeletal
muscles from these mice have abnormalities in signaling path-
ways that are involved in proliferation and differentiation (Melcon
et al., 2006) but no differences have been reported in the suscep-
tibility to this injury or the efficiency of tissue regeneration. Our600 Developmental Cell 26, 591–603, September 30, 2013 ª2013 Elscomparative examination of emerin and LAP1 expression in
mouse and human skeletal muscle suggest that mice may be
protected from emerin loss because of significantly higher levels
of LAP1 compared to humans.
Our finding that depletion of LAP1 frommuscle of emerin-defi-
cient mice causes a muscular dystrophy is reminiscent of the
relationship between dystrophin and utrophin in Duchenne
muscular dystrophy, a lethal X-linked inherited myopathy. Dys-
trophin loss-of-function causes Duchenne muscular dystrophy
(Hoffman et al., 1987a, 1987b) but deletion of dystrophin in
mdx mice leads to a milder progressive myopathy than in
humans. However, depletion of the functionally related protein
utrophin from mdx mice causes a severe phenotype similar to
Duchene muscular dystrophy (Deconinck et al., 1997; Grady
et al., 1997), even though utrophin deletion itself has little effect.
Similarly, LAP1, a nuclear envelope protein that binds to emerin,
appears to compensate for the loss of emerin in striated muscle
in mice. Because the utrophin-dystrophin-deficient mouse has
served as a small animal model for Duchenne muscular dystro-
phy, emerin-deficient mice with reduced or absent LAP1 in stri-
ated muscle may serve as models to study X-linked EDMD.
These examples highlight the importance of not focusing exclu-
sively on the ‘‘disease’’ protein when considering the reasons
for the presence or lack of phenotype in an animal model and
demonstrate how systematically probing species differences
can provide insight into disease pathogenesis. Finally, our
results indicate that LAP1 loss of function should be considered
in human subjects with EDMD phenotypes in which the genetic
cause has not been established, including those that may have
coexistent dystonia, because LAP1 also binds to torsinA (Good-
child and Dauer, 2005).
EXPERIMENTAL PROCEDURES
Complete methods can be found in the Supplemental Experimental
Procedures.
Cell Culture, Cell Lines, and Plasmids
Fibroblasts were isolated from E14-E16 mouse embryos and cultured in Dul-
becco’s Modified Eagle Medium supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin (all from Life Technologies) at 37C and 5%
CO2. HEK293 cells were from American Tissue Culture Collection and main-
tained under the same conditions. To generate a LAP1 expressing stable
cell line, a previously described full-length LAP1 cDNA fused to an N-terminal
V5 epitope tag (Kim et al., 2010) was subcloned into pcDNA5FRT/TO using the
Hind III and Xho I restriction sites. This plasmid was subsequently used for
generation of a stable, inducible cell line expressing V5-tagged full-length
LAP1 by transfection into Flp-In T-Rex-293 cells according to the manufac-
turer’s instruction (Life Technologies). Plasmids used for coimmunopre-
cipitation experiments, pull-downs, FRET, and FRAP are described in the
Supplemental Experimental Procedures.
Identification of LAP1-Interacting Proteins by Mass Spectrometry
Adoxycycline-inducible V5-tagged LAP1-expressing stable cell line was used.
Proteins were extracted from crude nuclear fractions obtained from uninduced
cells and cells induced with doxycycline and immunoprecipitation with anti-V5
antibodies (Life Technologies) was performed in buffer containing 1%Nonidet
P-40 as described in the Supplemental Experimental Procedures. After immu-
noprecipitation, bound proteins were eluted and separated by SDS-PAGE.
Bands visualized by silver staining and those in extracts of induced but not
uninduced cells were cut out and subjected to in-gel trypsin digestion followed
by liquid chromatography-mass spectroscopy/mass spectroscopy (Prote-
omics Resource Center, Rockefeller University).evier Inc.
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Coimmunoprecipitation was performed on protein extracts in buffer containing
1% Nonidet P-40 using anti-V5 affinity agarose (Life Technologies), anti-
emerin (Vector Labs, 4G5), or anti-immunoglobulin G1 (Santa Cruz) antibodies.
Coimmunoprecipitated proteins were separated by SDS-PAGE and identified
by immunoblotting with anti-V5 (Life Technologies), anti-emerin, anti-MAN1
(Pan et al., 2005), anti-LAP2b (Sigma), or anti-lamin A (Santa Cruz, H-102) an-
tibodies. Details are provided in the Supplemental Experimental Procedures.
Fusion Protein Purification and Pull-Down Assay
MBP-emerin fusion protein was purified using pMAL Protein Fusion and Puri-
fication System according to themanufacturer’s instruction (NewEnglandBio-
labs). Briefly, the first 222 amino acids of emerin fused to MBP was expressed
in Escherichia coli strain C2523 and induced at 32C for 3 hr with 0.3 mM iso-
propylthiogalactoside, purified using amylose resin, and then eluted with
20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA, and 10 mMmaltose con-
taining protease inhibitors. Eluted proteins were dialyzed in 25mMTris-HCl pH
7.4, 200 mM NaCl, and 1 mM EDTA. Plasmids encoding V5-tagged or GST-
tagged full-length LAP1 were transfected into HEK293 cells and expression
of fusion proteins was detected by immunoblotting with anti-V5 and anti-
GST (Sigma) antibodies. Additional details are provided in the Supplemental
Experimental Procedures.
FRAP and FRET
FRAP was performed as described (O¨stlund et al., 2009) and details are pro-
vided in the Supplemental Experimental Procedures. FRET was measured
by acceptor photobleaching using the FRET Wizard in the Leica Advanced
Fluorescence Application Suite (Huranova´ et al., 2009). HEK293 cells were
cotransfected with plasmids expressing the following protein pairs: EGFP-
LAP1/RFP-emerin, EGFP-lamin A/RFP-emerin, EGFP-LAP1/RFP, and EGFP/
RFP-emerin. After 24 hr, cells were fixed with 4% paraformaldehyde and
then washed with PBS. Cells with comparable levels of RFP and GFP fluores-
cence intensity were selected for analysis. Images were acquired with a 603
NA 1.40 oil objective on a laser-scanning confocal microscope (TCS SP5,
Leica). Regions of the nuclear envelope were photobleached with repeated
exposure to a 543 nm laser (100% power level). FRET efficiency (E) was calcu-
lated as the percentage increase in donor fluorescence after acceptor photo-
bleaching using the formula E = 1003(1GFPpre/GFPpost).
Human Subjects
Biopsy specimens of lateral quadriceps muscle were obtained from healthy
control subjects using the Bergstrom technique under local anesthesia. Sub-
jects were recruited from clinics at Columbia University Medical Center and
written informed consent obtained. Human liver samples were obtained from
the Herbert Irving Comprehensive Cancer Center tissue bank at Columbia
University. The Columbia University Medical Center Institutional Review Board
approved the protocols.
Mouse Breeding and Genotyping
The Institutional Animal Care and Use Committee of Columbia University
Medical Center approved all protocols. Mice were kept at room temperature
and fed normal chow. Tor1aip1 knockout mice were described previously
(Kim et al., 2010). Emerin knockout mice (Melcon et al., 2006) were kindly pro-
vided by Dr. Colin L. Stewart and maintained on a C57BL/6 background. Mice
carrying floxed alleles of Tor1aip1 (Tor1aip1f/f) were generated by insertion of a
targeting vector into the last exon (see Figure S1). They were crossed toMck-
Cre transgenic mice (Bru¨ning et al., 1998) or Alb-Cremice (Postic et al., 1999)
obtained from Jackson Laboratory (see Supplemental Experimental Proce-
dures for details). The mouse line carrying floxed alleles was crossed six times
onto the C57BL/6 background. Mice were monitored and body mass
measured weekly after weaning. Genotypes were determined by PCR analysis
using primers described in the Supplemental Experimental Procedures.
Serum Biochemistry
Serum biochemical analysis was performed on an AutoAnalyzer in the
Comparative Pathology Laboratory at Columbia University Medical Center
as described (Muchir et al., 2012). Serum was separated from blood and
stored at 80C until analyzed.DevelopmenGrip Strength Analysis
Grip strength was assessed using a published protocol (Spurney et al., 2009)
and a Chatillon DFIS-2 digital force gauge pull meter with angled mesh assem-
bly. Eachmouse was placed in front of the instrument and allowed to grasp the
pull bar with both forelimbs and hindlimbs and then pulled backward by its tail
until its grip was broken. Force applied to the bar the moment the grasp was
released was automatically recorded. Untrained mice were tested three times
in succession without rest.
Immunohistochemistry and Histopathological Analyses
Mouse skeletal muscle and liver were dissected and either fixed in 4% formal-
dehyde for 48 hr or rapidly frozen in liquid nitrogen-cooled isopentane for
sectioning on a cryostat. Cryosections were cut at 5-mm thickness and pro-
cessed for immunohistochemistry using on M.O.M kit (Vector Labs). Primary
antibodies were anti-LAP1, anti-emerin, anti-lamin A, and anti-lamin B1 anti-
bodies. Alexa Fluor 488 conjugated secondary antibody (Molecular Probes)
was used to visualize the primary antibody labeling. Coverslips were mounted
with Prolong Gold Antifade with 40,6-diamidino-2-phenylindole (DAPI, Life
Technologies) and images acquired with Zeiss Axiovert 200 M microscope
attached to a Zeiss LSM510 confocal laser scanning system (Carl Zeiss). Addi-
tional information is provided in the Supplemental Experimental Procedures.
To score histopathology, two independent neuromuscular pathologists
(A.P.H. and K.T.) performed blinded examination of hematoxylin and eosin-
stained stained sections from the quadriceps of 9- to 10-week-old mice.
Myofibers with central nuclei and necrosis/degeneration were scored from
examining four different sections per animal from seven mice per group.
Stained sections were graded from 0 to 3 according to severity: 0 = no pathol-
ogy, 1 = focal or regional myofiber degeneration/necrosis, 2 = obvious myo-
fiber degeneration/necrosis but less than 50% of total muscle area involved,
or 3 = obvious myopathy and higher than 50% of total muscle area involved.
Electron Microscopy
Electron microscopy was performed as described previously (Kim et al., 2010).
Briefly, 12-week-old control andM-CKOmicewere transcardially perfusedwith
4% paraformaldehyde/3% glutaraldehyde in 0.1 M sodium phosphate buffer
(pH 7.4). Quadriceps were dissected and postfixed with 1% osmium tetroxide
in 0.1 M cacodylate buffer (pH 7.4), incubated with uranyl acetate, and dehy-
drated with ethanol. Tissues were subsequently rinsed with propylene oxide
and embedded. Sections 60 nm thick were counterstained with uranyl acetate
and lead citrate and examined on a JEM-1200EX electron microscope (JEOL).
Statistics
Statistical significancewas determined by Student’s t test or one-way ANOVA.
GraphPad PRISM software (Version 4.0b) was used for the statistical analyses
and p < 0.05 was considered a statistically significant difference. Survival
curves were compared using the log-rank test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2013.08.012.
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